结果：药理评价显示甲磺酸培高利特是一典型D受体激动剂。
RESULTS:Pharmacological evaluation showed that Pergolide mesylate is a specific dopminergic DA receptor agonist.
FDA今天发布公共健康忠告，详细说明了培高利特撤市的情况。
FDA today is issuing a Public Health Adisory (PHA) detailing the remoal of pergolide products from the market.
培高利特的撤市希望对患者的治疗不会产生不利的影响，因为有其它的治疗药物可选择。
The removal of pergolide products is not expected to adversely affect patient care because of the alternative therapies available.
目的：使用麦角衍生的多巴胺激动剂，已经证实帕金森病人使用培高利特和卡麦角林可能增加瓣膜心脏病。
Objective: Treatment with ergot-derived dopamine agonists, pergolide, and cabergoline has been associated with an increased frequency of valvular heart disease in Parkinson's disease.
目的：使用麦角衍生的多巴胺激动剂，已经证实帕金森病人使用培高利特和卡麦角林可能增加瓣膜心脏病。
Objective: Treatment with ergot-derived dopamine agonists, pergolide, and cabergoline has been associated with an increased frequency of valvular heart disease in Parkinson's disease.
应用推荐